1Q: 2019 MARCH: Renalytix requests parallel CMS reimbursement review of KidneyIntelX with the FDA review Renalytix requests Breakthrough Device Designation of KidneyIntelX from the FDA By Elise Wilfinger|2023-01-18T09:30:19+00:0001.18.23|Comments Off on 1Q: 2019